SX-682

Item no.	V3258-250mg
Manufacturer	InvivoChem LLC
CASRN	1648843-04-2
Amount	250 mg
Quantity options	100 mg 10 mg 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Molecules
Type	Biochemicals
Specific against	other
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Description	InvivoChem Cat #:V3258CAS #:1648843-04-2Purity >=98% Description: SX-682 is a novel, potent and selective CXCR2 chemokine receptor antagonist with potential anticancer activities. The CXC chemokine receptor CXCR2 is upregulated in a variety of different tumor cell types and involved in tumor cell proliferation and progression. Inhibition of CXCR2 led to reduced metastasis and decreased tumorigenesis. As a CXCR2 antagonist, SX-682 has the potential to treat cancer such as castration-resistant prostate cancer and melanoma. SX-682 in combination with pembrolizumab for the treatment of metastatic melanoma is starting phase I clinical trial by Syntrix Biosystems, Inc. Description: References: Nature. 2017 Mar 30; 543(7647):728-732. References:
Molecular Weight (MW)	467.20
Formula	C19H14BF4N3O4S
CAS No.	1648843-04-2
Storage	-20C for 3 years in powder form
	-80C for 2 years in solvent
Solubility (In vitro)	DMSO: 10mM
	Water: < 1 mg/mL
	Ethanol: < 1 mg/mL
Chemical Name	(2-(((5-((4-fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid
Synonyms	SX-682; SX 682; SX682
SMILES Code	O=C(C1=CN=C(SCC2=CC(OC(F)(F)F)=CC=C2B(O)O)N=C1)NC3=CC=C(F)C=C3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 250 mg

available

Delivery expected until 9/4/2025

Compare

Add to wishlist

Get an offer

Request delivery time